Insmed's 82.5% gross margins cannot overcome -$248M quarterly cash burn, creating a rare disease specialist that destroys capital at premium prices.
This framework sees a rare disease specialist with exceptional gross margins burning cash at unsustainable rates while the market prices in a transformation that may never arrive.
Would an owner of this business be able to take home real cash after maintaining operations?
This framework finds deeply troubling cash economics. Despite explosive revenue growth and the elimination of stock dilution, the business consumes $248M quarterly with no path to positive owner earnings visible. An owner would need to continuously inject capital rather than extract it.
Does this business have durable competitive advantages that protect its economics?
The framework recognizes exceptional pricing power in rare disease markets, evidenced by 82.5% gross margins at the 93rd percentile historically. However, the inability to translate this pricing advantage into positive operating margins suggests the moat protects price but not profitability.
If you bought this entire business today, would what it earns justify what you paid?
Applying this framework's permanent owner mindset, the math is indefensible. A business losing $1.28B annually trading at a 209.7% premium to its already negative DCF value represents speculation, not investment. The -5.21% spread to treasuries means an owner pays to lose money.
Are managers acting as owners or agents?
This framework finds troubling stewardship signals. Management's persistent selling while the company burns cash and trades at extreme valuations suggests they view their own equity as overvalued. The debt reduction provides modest comfort but cannot offset the insider exodus.
This framework sees a business with undeniable pricing power in rare diseases that cannot translate that advantage into owner earnings. The 82.5% gross margins prove the products have value, but the -$248M quarterly cash burn proves the business model does not. When insiders flee while institutions pile in at a 209.7% premium to negative fair value, someone misunderstands this business fundamentally. Is it possible to build a great business that never makes money?
This analysis applies Warren Buffett's published investment framework to publicly available financial data. It is not authored by, endorsed by, or affiliated with Warren Buffett. Educational purposes only. Not financial advice.